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Cellular stress responseOver the past two decades, a complex nuclear transcriptional machinery controlling mitochondrial biogene-
sis and function has been described. Central to this network are the PGC-1 family coactivators, characterised
as master regulators of mitochondrial biogenesis. Recent literature has identiﬁed a broader role for PGC-1
coactivators in both cell death and cellular adaptation under conditions of stress, here reviewed in the con-
text of the pathology associated with cancer, neurodegeneration and cardiovascular disease. Moreover, we
propose that these studies also imply a novel conceptual framework on the general role of mitochondrial dys-
function in disease. It is now well established that the complex nuclear transcriptional control of mitochon-
drial biogenesis allows for adaptation of mitochondrial mass and function to environmental conditions. On
the other hand, it has also been suggested that mitochondria alter their function according to prevailing cel-
lular energetic requirements and thus function as sensors that generate signals to adjust fundamental cellular
processes through a retrograde mitochondria-nucleus signalling pathway. Therefore, altered mitochondrial
function can affect cell fate not only directly by modifying cellular energy levels or redox state, but also indi-
rectly, by altering nuclear transcriptional patterns. The current literature on such retrograde signalling in
both yeast and mammalian cells is thus reviewed, with an outlook on its potential contribution to disease
through the regulation of PGC-1 family coactivators. We propose that further investigation of these pathways
will lead to the identiﬁcation of novel pharmacological targets and treatment strategies to combat disease.
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Fig. 1. Structure of the PGC-1 family coactivators. Schematic comparison of PGC-1α,
PGC-1β and PRC with the identities and function of the conserved sequence motifs
shown in the key at the bottom.
Modiﬁed from (Scarpulla, 2011).
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Cellular control of the complex signalling network responsible for
maintaining a proper and functional mitochondrial population is cur-
rently emerging as a central conundrumassociatedwith a growing num-
ber of pathophysiological processes. Novel research ﬁelds converge upon
this central theme, encompassingmitochondrial dynamics, selective mi-
tochondrial autophagy, maintenance of the mitochondrial genome
(mtDNA), and quality control of mitochondrial protein complexes. At
the level of the whole organelle, it has been proposed that dysfunctional
mitochondria, ﬂagged by loss of their membrane potential (ΔΨm), are
separated from the intact, polarised network by ﬁssion and can either
be recycled by subsequent fusionwith ‘healthy’mitochondria or degrad-
ed through autophagy, representing the ‘mitochondrial life cycle’
(reviewed in (Twig et al., 2008)). Similarly at the molecular level, mis-
folded and damaged mitochondrial proteins are degraded by organelle
speciﬁc proteases (for reviews see (Luce et al., 2010; Tatsuta and Langer,
2008)), and defective mtDNA can be segregated, a phenomenon which
may lead to major depletion of mtDNA copy number (Holt, 2010). In-
deed, radioactive 14C pulse-chase experiments (Miwa et al., 2008) have
estimated the half-life of the cellular mitochondrial pool in hepatocytes
in vivo to be only≈40 h. If left unopposed these quality control mecha-
nisms would lead to rapid depletion of mitochondrial mass, thus an
equally active biogenesis system must be in operation in order to con-
stantly replenish the healthy cellular mitochondrial pool. The biogenesis
of mitochondria involves multiple processes, including: (i) formation of
the double membrane boundary from phospholipids, which are either
imported from other organelles or synthesised locally (Horibata and
Sugimoto, 2010; Potting et al., 2010; Tamura et al., 2009; Vance and
Vance, 2004); (ii) import of mitochondrial proteins which are encoded
by nuclear genes, representing the large majority of the mitochondrial
proteome; (iii) synthesis of the few, but nonetheless fundamental,
mtDNA encoded protein components of the electron transport chain
(ETC) in the matrix (Calvo and Mootha, 2010; Schmidt et al., 2010;
Sickmann et al., 2003); and (iv) replication of themitochondrial genome
and translational machinery (Shutt and Shadel, 2010; Wallace, 2007).
These four processes are inherently interrelated in order to achieve a bal-
anced assembly of the organelle (Gohil and Greenberg, 2009; Scarpulla,
2006). Moreover, since mitochondrial function is dynamically regulated
to facilitate adaptation to cellular activity, mitochondrial biogenesis re-
quires the concerted regulation of the expression of nuclear encoded
genes, which ultimately enable each of these processes.
Reﬂecting the complexity and importance of the control of the mi-
tochondrial biogenesis machinery, expression of the mitochondrial
proteome, estimated to comprise approximately 1500 protein species
(Pagliarini et al., 2008), is regulated by a plethora of nuclear factors in
a hierarchical manner. Early work, pioneered by the group of Scar-
pulla, identiﬁed a set of DNA binding transcription factors (TFs) re-
sponsible for the induction of cytochrome c and cytochrome oxidase
subunit genes, thus named nuclear respiratory factor 1 and 2 (NRF-
1 and 2, the latter is a homologue of the mouse GA binding protein
[GABP], for reviews see (Scarpulla, 2006, 2008a)). In addition, NRFs
also indirectly control the expression of mtDNA encoded genes by po-
tently inducing the nuclear encoded mitochondrial transcription fac-
tors A, B1 and B2 (TFAM, TFB1M and TFB2M, respectively), regulators
of the transcription and replication of the mitochondrial genome
(Scarpulla, 2008b). Further TFs were consequently associated with
regulation of mitochondrial genes, such as the cAMP response ele-
ment binding protein (CREB) (Gopalakrishnan and Scarpulla, 1994)
and initiator element binding factor (YY1) (Basu et al., 1997). Impor-
tantly, the transcriptome regulated by these TFs extends beyond tran-
scripts encoding mitochondrial proteins (Cam et al., 2004) to those
required for broad cellular function, and cell type speciﬁc TFs exist,
such as myocyte enhancer factor-2 (MEF2) and E-box binding factors
in striated muscle (Lenka et al., 1996; Wan and Moreadith, 1995). Inaddition, taking the transcriptional regulation of mitochondrial bio-
genesis to a higher level, the expression of speciﬁc sets of mitochon-
drial proteins is controlled as part of larger transcriptional networks
directed by diverse extracellular and intracellular signalling pathways
responsible for regulating cellular lipid and carbohydrate metabolism,
the detoxiﬁcation of harmful agents, cell growth and differentiation.
These factors, acting in cis- or trans-, regulate the expression of mito-
chondrial proteins either directly in their speciﬁc promoter region or
indirectly, acting through modulation of the expression of primary
TFs, such as NRF-1 and 2. Control of mitochondrial biogenesis by thy-
roid and steroid hormones is achieved through nuclear receptors
(NRs) for thyroid hormones (TRs) (Marin-Garcia, 2010), glucocorti-
coids (GR) (Connaughton et al., 2010), testosterone (Qin et al.,
2010) and estradiol (ERα) (Klinge, 2008), along with a series of or-
phan NRs: peroxisome proliferator-activated receptor (PPARα and
γ), estrogen related receptor NRs (ERRα and γ), hepatocyte nuclear
factor 4α (HNF-4α) and the liver X receptor (LXR) (Hock and Kralli,
2009). In addition, NRs activated by xenobiotics have also been sug-
gested to modulate mitochondrial function by transcriptional regula-
tion, such as the constitutive androstane receptor (CAR) and the
pregnane X receptor (PXR)(Wada et al., 2009). Finally, c-myc mediat-
ed induction of mitochondrial biogenesis orchestrates the integration
of mitochondrial function with cellular growth and proliferation,
whilst both direct and indirect repression of mitochondrial metabo-
lism and oxidative activity by hypoxia inducible factor (HIF-1α) aids
adaptation to hypoxic conditions.
Investigation into a further level of integration in nuclear tran-
scriptional regulation of mitochondrial biogenesis has been instigated
by the discovery of the nuclear coactivator PPARγ coactivator-1α
(PGC-1α), a member of the ever-growing family of nuclear coregula-
tors. Coregulators exist and function in large multiprotein complexes,
in which rather than binding to DNA, they engage NRs and TFs and
modulate their transcriptional potency by promoting the subsequent
biochemical interactions required for induction or repression of gene
transcription. These interactions include allosteric modiﬁcation of
DNA binding by TFs and NRs, chromatin modiﬁcation and remodel-
ling, initiation of transcription and mRNA editing (see (O'Malley and
Kumar, 2009) and references therein). PGC-1α was cloned ﬁrst in
the mouse (Puigserver et al., 1998) and subsequently in humans
(Esterbauer et al., 1999) as a coregulator of the NRs PPARγ and TR
driving adaptive thermogenesis in brown adipocytes, and as a factor
playing a role in the differentiation of this cell type (reviewed in
(Kajimura et al., 2010; Spiegelman et al., 2000)). This seminal ﬁnding
was soon followed by the identiﬁcation of a series of TFs (NRF1 and
2α, YY1 and MEF2C acting directly on the ETC; the SREBP family
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γ, PPARα and FXR (Zhang et al., 2004) also acting on lipid metabo-
lism) coregulated by PGC-1α, establishing its role as the ‘master reg-
ulator’ of mitochondrial biogenesis (Wu et al., 1999). Further
members of a small family of structurally related transcriptional coac-
tivators have also been cloned via their homology to PGC-1α (Fig. 1.),
named PGC-1β (Kressler et al., 2002; Lin et al., 2002a) and PGC-1α re-
lated coactivator (Andersson and Scarpulla, 2001) (PRC), as well as a
truncated alternatively spliced isoform, NT-PGC-1α (Zechner et al.,
2010; Zhang et al., 2009). Genetic approaches have established the
complimentary function of PGC-1α and PGC-1β in maintaining an ap-
propriate mitochondrial density in tissues with high energy demand,
as clearly demonstrated by the recently created double knockout
mice, which show markedly reduced mitochondrial number and
size in brown adipose tissue, skeletal muscle and cardiac muscle, as-
sociated with cardiac failure soon after birth (Lai et al., 2008; Zechner
et al., 2010). On the contrary, although PRC also shares the core mito-
chondrial biogenetic function of PGC-1α and PGC-1β, its tissue specif-
ic expression levels do not correlate with mitochondrial density,
rather with the proliferative status of the cell (Andersson and Scar-
pulla, 2001; Vercauteren et al., 2006).
Whilst the principal function of the PGC-1 family of coactivators –
master regulators of mitochondrial biogenesis – is now relatively well
established, at least three further lines of evidence indicate that a
broader spectrum of cellular activities is also under their surveillance,
namely: (i) In addition to acting as coactivators to NRs, PGC-1 family
members engage in interactions with other nuclear coactivators and
corepressors, representing a further level of complexity in the regula-
tion of cellular functions in a tissue speciﬁc manner, the implications
of which remain to be elucidated. These interactions mediate chroma-
tin remodelling and either promote (CBP/p300, SIRT1, Baf60a, Lipin)
or repress (Rip140, GCN5, Sin3A) PGC-1 family function (reviewed
in (Hock and Kralli, 2009; Lin, 2009)); (ii) The PGC-1 family is respon-
sible for the regulation of a broad range of additional relatedmetabolic
functions not themselves intrinsic to mitochondria. For instance,
PGC-1α activates a large set of genes, termed oxidative phosphorylation
(OXPHOS)-coregulated genes, mediating insulin-dependent glucose
disposal primarily in the heart, brown adipose tissue and skeletal mus-
cle (Mootha et al., 2003), in addition to a strong dependence of hepatic
gluconeogenesis and fatty acid oxidation on PGC-1β (Ling et al., 2004),
PGC-1α additionally coordinates heme biosynthesis (Handschin et al.,
2005) and triglyceride metabolism (Zhang et al., 2009); (iii) Finally,
the complex hierarchical nuclear regulatory network outlined above is
a target for a range of fundamental cellular signalling pathways,
whichmodulate the activity of the PGC-1 familymembers either by reg-
ulating their expression levels or through post-translational modiﬁca-
tions (recently reviewed in (Hock and Kralli, 2009; Lin et al., 2005a;
Scarpulla, 2011)). Energy deprivation, that is decreased intracellular
ATP/AMP and NADH/NAD+ratios, activates PGC-1α both by phosphor-
ylation through the AMP activated protein kinase (AMPK) pathway or
by sirtuin (SIRT1) mediated deacetylation. Cellular energy status also
signals to PGC-1α through mammalian target of rapamycin (mTOR)
and YY1, and intriguingly, the regulation of PGC-1α activity by exercise
and cold exposure is also under the control of stress signalling via the
MAPK pathway, as well as through cellular Ca2+ and cAMP signalling
(Hock and Kralli, 2009). An additional route of signalling from mito-
chondria to NRs and coregulators might also operate in a retrograde
manner to directly couple the functional status and requirements of
these organelles to the nuclear transcription programme. The ﬁnal sec-
tion of this review will further elaborate upon this concept.
Altogether, the highly complex function and regulatory network of
the PGC-1 family which has been unravelled during the last decade
may well be only the tip of the iceberg, but nonetheless clearly indicate
that these transcriptional coregulators are engaged in fundamental
mechanisms determining cellular activity, and ultimately cell fate.
Indeed, deregulation of PGC-1 family function now appears to underliemajor pathologies. Loss of the PGC-1 family activity will inevitably lead
tometabolic derangements, which in turnwill affect cell growth, prolif-
eration and cell survival. Alternatively, nuclear rearrangement of gene
regulatory elements associated with the function of these coregulators
might directly modify the expression of components of cell death and
pro-survival pathways. In the next two sections we shall: (i) brieﬂy
summarise the existing data in which PGC-1 family activity may exert
an inﬂuence upon cell fate, and the associated pathologies which may
result, and (ii) examine the hypothesis that primary mitochondrial
dysfunction leading to energy deprivation could signal to the nuclear
transcriptome through the PGC-1 family, instigating either protective
or maladaptive mechanisms contributing to disease. We believe that
critical evaluation of these studies is necessary to assess the suitability
of these molecules or pathways as pharmacological targets.
2. PGC-1 family coactivators and cell survival
The regulation of cell fate is a complex process, and relies upon the
balance and integration of multiple opposing ‘pro-survival’ and ‘pro-
death’ signalling pathways. Should signals promoting cell death
come to predominate over those for continued growth and survival,
cellular elimination may occur through several deﬁned routes. The
best characterised of these routes is apoptosis, a genetically encoded
cell death programmewhich leads to the ordered dismantling of cellular
architecture and proceeds through a set of distinctmorphological stages,
including chromatin condensation and nuclear fragmentation (Galluzzi
et al., 2007; Kroemer et al., 2009). This dismantling is mediated through
the action of caspase enzymes, a class of cysteine-dependent aspartate-
speciﬁc proteases, which may be activated after the release of pro-
apoptotic factors from the mitochondrial inter-membrane space dur-
ing the intrinsic pathway of apoptosis. The release of such factors occurs
only after permeabilisation of the outer mitochondrial membrane, the
integrity of which is in turn regulated by the competing action of mem-
bers of the BCL-2 family of proteins (reviewed in (Chipuk et al., 2010;
Youle and Strasser, 2008)) upon which both survival and death signals
converge. Cell deathmay also occur via necrosis, the abrupt swelling and
rupture of cellular organelles and the plasmamembrane,whichmay fol-
low loss of ΔΨm during mitochondrial permeability transition (Galluzzi
et al., 2007; Halestrap, 2009; Kroemer et al., 2009). Mitochondria are
thus key regulators of cell fate.
The mitochondrial route to cell death may be activated by multi-
ple stimuli including the developmental programme, DNA damage,
ER stress, growth factor and nutrient deprivation, viral infection and
oxidative stress (Youle and Strasser, 2008). However, abnormalities
in invoking cell death pathways lie at the heart of distinct pathologies.
Aberrant induction of cell death may result in conditions as diverse as
neurodegeneration, ischemia reperfusion injury and autoimmune
disease (Fadeel and Orrenius, 2005), whilst conversely failure to un-
dergo death is a key stage in the malignant transformation of cancer
cells (Hanahan and Weinberg, 2000). Recent evidence has begun to
identify a role for the PGC-1 family of nuclear coregulators in cell
fate determination, and in diseases which may arise from dysregula-
tion of this function.
2.1. Neurodegenerative diseases
Neurodegenerative disorders result from progressive loss of function
and cell death within neuron populations, exempliﬁed by Alzheimer's
disease (AD), Parkinson's disease (PD), Huntington's disease (HD)
and amyotrophic lateral sclerosis (ALS) amongst others. The systemic
manifestation of these diseases results from loss of speciﬁc subsets of
neurons. The PGC-1 family was directly implicated in neurodegenera-
tionwith the creation of the PGC-1α knockout (PGC-1α−/−) transgenic
mouse model. PGC-1α−/− mice display marked hyperactivity accom-
panied by neuronal degeneration and lesions predominantly in the
striatum, with less prominent lesions in cortical regions (Lin et al.,
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PGC-1α−/− mouse model in which vacuolar lesions of the central
nervous system were observed (Leone et al., 2005), positing a role
for PGC-1α in the maintenance of neuronal function.
The involvement of PGC-1 family coactivators in neurodegenerative
disorders has been further implied by genetic studies. The regulation of
lifespan and increased risk of the development of both PD and HD have
been shown to be associated with single nucleotide polymorphisms in
the gene encoding PGC-1α (PPARGC1A) (Clark et al., 2011; Weydt
et al., 2009), whilst sequence variations in PGC-1α target genes such
as TFAM and NRF-1 were identiﬁed in AD and HD patients (Maruszak
et al., 2011; Taherzadeh-Fard et al., 2011). Decreased expression of
PGC-1α has also been reported in AD, HD and PD patients, as well
as in mouse models of HD and spinal and bulbar muscular atrophy
(Cui et al., 2006; Qin et al., 2009; Ranganathan et al., 2009; Weydt
et al., 2006; Xiang et al., 2011; Zheng et al., 2010). Such repression
of PGC-1α has been attributed to mutant nuclear huntingtin (Cui
et al., 2006) or a parkin dysfunction mediated mitochondrial-nuclear
pathway (Shin et al., 2011). Accordingly, forced expression of PGC-1α
in neuronal cell cultures signiﬁcantly abrogated cell death induced by
both 3-nitropropionic acid (a pharmacological model of HD) (Weydt
et al., 2006). Overexpression of PGC-1α in HD mouse muscle ﬁbres re-
stored the muscular capacity for oxidative phosphorylation under
chronic energy deprivation conditions (Chaturvedi et al., 2009), while
up-regulation of the coactivator by the kinaseMSK-1 attenuated neuro-
nal cell death induced by mutant huntingtin protein (Martin et al.,
2011). Furthermore, overexpression of PGC-1α also improved the
motor performance and survival of a SOD-1 G93A transgenic ALS
mouse model (Zhao et al., 2011). Due to the emerging role of PGC-1α
in multiple neurodegenerative pathologies, strategies for pharmacolog-
ical activation of the coactivator have recently gainedmuch attention as
a potential novel avenue of treatment for these diseases (Handschin,
2009; Wenz, 2009, 2011; Wenz et al., 2010; Zorzano et al., 2010).
Both PGC-1α and PGC-1β have been demonstrated to trigger pro-
tective mechanisms under conditions of oxidative stress, providing an
appealing hypothesis to explain their beneﬁcial role in preventing de-
generative diseases. In murine myoblasts the abundance of mitochon-
drial respiratory complexes and uncoupling proteins was increased
through overexpression of exogenous PGC-1α or PGC-1β, accompanied
by a concomitant increase in the expression of genes associated with
detoxiﬁcation of both mitochondrial and cytosolic reactive oxygen spe-
cies (ROS) (St-Pierre et al., 2003). PGC-1α overexpression in SH-SY5Y
neuroblastoma cells also resulted in increased expression ofmanganese
superoxide dismutase (MnSOD) (Cowell et al., 2009). Furthermore, ex-
posure to H2O2 augmented both PGC-1α and PGC-1β gene expression
in mouse embryonic ﬁbroblasts, along with the previously reported in-
crease in antioxidant capacity, whilst silencing of PGC-1α alone or si-
multaneous silencing of PGC-1α and PGC-1β blunted the enhanced
expression of ROS detoxiﬁcation enzymes (St-Pierre et al., 2006), sug-
gesting a potential cytoprotective role for these coregulators during ox-
idative stress. Accordingly, PGC-1α−/− mice were shown to be
sensitised to neuronal cell death caused by MPTP or kainic acid, whilst
overexpression of PGC-1α in murine striatal neuron progenitor cells
signiﬁcantly decreased cell death induced byH2O2 or paraquat, a super-
oxide generating agent (St-Pierre et al., 2006). SH-SY5Y cells overex-
pressing PGC-1α were also protected from H2O2 treatment, with a
reduction in caspase-3 activation (Cowell et al., 2009; St-Pierre et al.,
2006). The neuroprotective effects of PGC-1αwere recently potentially
extended to conditions of oxygen and glucose deprivation, underwhich
PGC-1α overexpression suppressed apoptosis in primary mouse corti-
cal neurons (Luo et al., 2009).
2.2. Cardiovascular diseases
The ability of PGC-1 family coactivators to increase cellular antioxi-
dant defences also underpins a protective effect in the vascularendothelium. As for neuron models, increased expression of PGC-1α
in human vascular endothelial cells (HUVEC) led to mitochondrial bio-
genesis and an increased complement of ROS detoxiﬁcation proteins,
includingMnSOD (Valle et al., 2005). Exposure to ROS also upregulated
PGC-1α expression and the cellular antioxidant capacity of bovine en-
dothelial cells (Borniquel et al., 2006). HUVEC overexpressing PGC-1α
produced fewer intracellular ROS and displayed an inhibition of cas-
pase-3 activation with increased cell viability after oxidative stress in-
duced by DMNQ, H2O2 and high glucose conditions (Valle et al.,
2005). Suppression of ROS detoxiﬁcation by post-translational inhibi-
tion of the transactivation activity of PGC-1α may lie behind vascular
hypertrophy induced by angiotensin II (Xiong et al., 2010). PGC-1α
was further seen to prevent apoptosis of endothelial cells triggered by
fatty acids, apparently mediated through increased expression of the
adenine nucleotide transporter 1 (Won et al., 2010).
Gene knockout models of the PGC-1 family coactivators have also
revealed a role in maintaining proper cardiac function. Both
PGC-1α−/− and PGC-1β knockout (PGC-1β−/−) transgenic mice pre-
sent with modest heart defects and are less able to increase cardiac
work output in response to either chemical or electrical stimulation
(Arany et al., 2006; Lelliott et al., 2006; Leone et al., 2005). Moreover,
double transgenic knockout of PGC-1α and PGC-1β in mice results in
early postnatal heart failure as the primary cause of lethality (Lai
et al., 2008). Similarly, diminished PGC-1α expression correlates
with stress induced cardiac failure (Arany et al., 2006; Sano et al.,
2004) and cardiomyocyte cell death in a mouse model of congestive
heart failure (Garnier et al., 2003). Indeed, PGC-1α has been sug-
gested to play a key role in physiological cardiomyocyte metabolism
and growth (Arany et al., 2005; Czubryt et al., 2003; Huss and Kelly,
2004). However, in contrast to neuronal models, forced expression
of PGC-1 family proteins is not necessarily beneﬁcial in cardiac cells.
Whilst overexpression of PGC-1α was shown to block PARP cleavage,
caspase-3 activation and apoptosis of cardiomyocytes in an in vitro
model of stress-induced cardiac failure (Arany et al., 2006; Sano
et al., 2004), it also delayed mouse cardiac contractile recovery after
an ischemic episode, and increased cardiomyocyte cell death under
anoxia (Lynn et al., 2010) and caused transient cardiomyopathy
during development (Russell et al., 2004).
2.3. Cancer
Cancer results from the imbalance of cell proliferation over cell
death. Acquired resistance to the initiation of cell death processes is
a key stage in tumour development (Hanahan and Weinberg, 2000),
and increased levels of expression of the PGC-1 family coactivators
have been observed in cancer cells (Savagner et al., 2003; Shiota
et al., 2010; Srivastava et al., 2007), which may be associated with a
pro-survival effect. Mitochondrial cell death pathways can be trig-
gered by pathological Ca2+ accumulation in the mitochondrial matrix
(Duchen et al., 2008; Orrenius et al., 2003). Overexpression of PGC-1α
in both a cervical cancer (HeLa) cell line and rat skeletal myotubes
markedly reduced mitochondrial Ca2+ uptake during Ca2+ signalling
stimulated by physiological ligands; importantly, this modiﬁcation of
organelle Ca2+ homeostasis also protected HeLa cells from death in-
duced by C2 ceramide and staurosporine (Bianchi et al., 2006). The
protective effect was related to increased mitochondrial biogenesis,
providing a direct link between PGC-1α transcriptional activity and
cell fate. The transactivation activity of PGC-1β may also inﬂuence
the sensitivity of cancer cells to death inducing stimuli. PGC-1β is re-
quired for increased gene expression activity at the 17q12-21 chro-
mosomal region, a set of genes often ampliﬁed in breast cancer and
associated with a poor prognosis. Silencing of PGC-1β mediated by
siRNA in tamoxifen-resistant MCF-7 breast cancer cells restored the
tamoxifen sensitivity in this cell line (Deblois et al., 2010). However,
no direct mechanistic link between the extrinsic pathway of apoptotis
and the PGC-1 family of coactivators has yet been found.
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must also alter intracellular metabolism to meet the demands of rapid
cellular proliferation in the unique tumour microenvironment, referred
to as metabolic reprogramming (DeBerardinis et al., 2008). As master
regulators of cellular metabolism, the PGC-1 family members may
orchestrate changes inmetabolism capable of sustaining a rapid growth
phenotype. The PGC-1β dependent amplicon at the 17q12-21 chromo-
somal region has also been associated with the growth of certain types
of breast cancer, and silencing of PGC-1β reduced the proliferative rate
of a breast cancer cell line (Deblois et al., 2010). Similarly, silencing of
PRC in osteosarcoma cells inhibited proliferation in both glucose and ga-
lactose based culture medium, accompanied by cell cycle arrest in G1
phase, suggesting that PRC function may support both mitochondria
dependent and independent cell growth and proliferation (Vercauteren
et al., 2009). Functional PGC-1αmight be required for efﬁcient growth
and proliferation of prostate cancer cells, since siRNA mediated PGC-
1α silencing reduced proliferative rates and caused G1 phase cell
cycle arrest in both hormone-sensitive and hormone-insensitive pros-
tate cancer cell lines (Shiota et al., 2010). Signiﬁcantly increased PGC-
1α expression levels were measured in tumour samples obtained
from arsenic-induced skin cancer patients, and may be associated
with increased cellular proliferation (Lee et al., 2011), whilst a similar
mechanism, triggered by a mitochondria-nucleus retrograde signalling
pathway, has been proposed to drive oncocytic tumorigenesis. PGC-
1α stimulation may also be capable of activating the biosynthetic
PI3K/Akt growth pathway, since pharmacological activation of PGC-
1α promoted proliferation and Akt activation in H1838 and H2106
non-small cell lung cancer cell lines (Han et al., 2009). Overexpression
of PGC-1α also increased the expression of uridine phosphorylase, an
enzyme involved in the pyrimidine salvage pathway often upregulated
by cancer cells, and increased proliferation in both breast and colon can-
cer cell lines (Kong et al., 2009). PGC-1αmay potentially stimulate both
cell growth and cancer cell survival throughHIF TFs, since PGC-1α over-
expression in rat skeletalmyotubes upregulatedHIF-2α, a TF previously
associated with tumourigenesis and chemoresistance (Majmundar
et al., 2010; Rasbach et al., 2010; Roberts et al., 2009).
However, the role of the PGC-1 family in controlling cancer cell fate
appears to be complex, and not invariably beneﬁcial. Indeed, forced
expression of PGC-1α resulted in apoptosis of human epithelial ovarian
cancer cells (Zhang et al., 2007b), and several studies have revealed
signiﬁcantly decreased PGC-1 coactivator expression in tumour samples
(Feilchenfeldt et al., 2004; Jiang et al., 2003; Watkins et al., 2004).
Accordingly, PGC-1 driven mitochondrial biogenesis impeded cancer
cell proliferation under glycolytic conditions (Wang and Moraes,
2011), and miRNA mediated downregulation of PGC-1 was shown
to mediate coordinated changes in the hepatocyte metabolic network
promoting hepatocarcinogenesis (Burchard et al., 2010).
2.4. Summary: An emerging cohesive role of the pgc-1 family in cell
survival, growth and proliferation?
As summarised in Table 1, the expression of the PGC-1 family
coactivators plays a broadly cytoprotective role in cellular physiology,
promoting cell growth, proliferation and survival after apoptotic
stimuli. Accordingly, expression of PGC-1α improves several neuro-
degenerative, cardiovascular and other age related pathologies, as
discussed above. Moreover, recent pharmacological approaches in a
number of pathologies have been aimed at exploiting the activation
of PGC-1α through multiple routes, including the PPARγ pathway
using ﬁbrates, the SIRT1 pathway using resveratrol and the AMPK
pathway using AICAR. A detailed summary of these works is beyond
the scope of this review, for recent updates see (Handschin, 2009;
Wenz, 2009, 2011; Zorzano et al., 2010). It should be noted however
that PGC-1 family expression may not always be beneﬁcial. As several
examples discussed above demonstrate, overactivation of the meta-
bolic and signalling networks controlled by these coactivators mightlead to reduced proliferation and even cytotoxicity in cardiac tissue
as well as in cancer cells, thus it is plausible that the speciﬁc effects
of PGC-1 family coactivators depend upon the actual environmental
and metabolic context of the cell. Fine tuning of the activation differ-
ent members of the family and their interactions with other TFs might
thus have differential effects on cell fate, leaving outstanding open
questions for future research.
3. Mitochondrion–nucleus retrograde signalling and its role in cell
fate and disease pathology
As discussed above, PGC-1 family coactivators play an important
role in inﬂuencing cell fate, and their deregulation is frequently asso-
ciated with disease states. Regulation of both the expression and the
activity of PGC-1α and PGC-1β is under the control of cellular energy
and redox status, which in turn is ultimately governed by mitochon-
drial activity. We thus propose that primary mitochondrial dysfunc-
tion may contribute to alterations in the activity of the PGC-1 family
through a retrograde mitochondrion–nucleus signalling pathway
and play a part in the pathomechanism of at least a subset of mito-
chondria related diseases. These alterations might represent adaptive
changes to re-establish normal mitochondrial function, but may also
directly regulate cellular fate, leading either to cellular survival or to
maladaptive responses, aggravating disease. Here we ﬁrst brieﬂy re-
view the available information on mitochondrion–nucleus retrograde
signalling, then discuss its certain pathological aspects, with empha-
sis on the potential role of PGC-1 family coactivators.
3.1. The prototypic mitochondrion–nucleus retrograde signalling pathways
in yeast
Amitochondrial homeostatic system in yeast, involving mitochon-
drial-nuclear intergenomic communication was ﬁrst demonstrated
by the group of Butow (Parikh et al., 1987). Interestingly, these
early observations revealed that loss of mtDNA triggered the upregu-
lation not only of nuclear encoded mitochondrial genes such as cyto-
chrome oxidase subunit VI, as may be expected as part of an adaptive
negative feedback loop, but also several genes encoding non-mito-
chondrial proteins, and even non-translated nuclear ribosomal RNAs
(Butow et al., 1988). Accordingly, the CIT2 gene encoding the peroxi-
somal isoform of citrate synthase has been identiﬁed as a prototypical
target of the mitochondrion–nucleus signal transduction pathway
(Liao et al., 1991). The backbone of the pathway comprises two tran-
scription factors, Rtg1p and Rtg3p, which bind the R-box consensus
site (GTCAC). The assembly, nuclear translocation and consequent ac-
tivation of these TFs are controlled by a cascade of cytoplasmic regu-
lators (reviewed in (Liu and Butow, 2006)). Importantly, amongst
these cytoplasmic factors the activator Rtg2p requires ATP binding,
and was suggested to respond to NH4+, glutamine and glutamate
levels, compatible with a putative role as a metabolic sensor, whilst
the inhibitor Lst8p is an essential component of both target of rapa-
mycin (TOR) complexes 1 and 2, the evolutionarily conserved hubs
of the yeast nutrient sensing pathway (Chen and Kaiser, 2003; Liu
et al., 2001). Indeed, the set of Rtg target genes identiﬁed thus far
aligns with metabolic pathways responsible: (i) adaptation to the
dysfunction of mitochondrial respiration by upregulating the partly
peroxisomal glyoxylate cycle for the oxidation of fatty acids and two
carbon sources, (ii) maintenance of mtDNA by the bifunctional TCA
cycle enzyme aconitase (encoded by ACO1) (Chen et al., 2005) and
(iii) the anaplerosis of a truncated TCA cycle in the absence of succinate
dehydrogenase activity in order to provide substrates for glutamate and
lysine synthesis, ensuring the requirement for nitrogen for anabolic re-
actions is fulﬁlled (Epstein et al., 2001; Magasanik and Kaiser, 2002).
However, several lines of evidence indicate that while the path-
way thus far described plays an essential role in cellular homeostasis,
it might represent only one arm of mitochondrion–nucleus signalling.
Table 1
Modulation of cell fate by PGC-1 family coactivators in neuronal, cancer and cardiovascular models. Listing studies reporting the effects of experimental modulation of the
expression/activity of PGC-1α, β or PRC.
Family
member
Experimental system Effect on cell fate Reference
Modiﬁcation Cell type PGC-1 promotes
cell survival?
Neurodegeneration
PGC-1α Knockout Mouse dopaminergic neurons ✓ Sensitises to MPTP and kainic acid induced cell death. (St-Pierre et al.,
2006)Overexpression Mouse striatal neuronal progenitor
cells
✓ Protects against paraquat and H2O2 induced cell death.
PGC-1α Overexpression SH-SY5Y neuroblastoma cell line ✓ Protects against H2O2-induced cell death and inhibits
caspase 3 activation.
(Cowell et al.,
2009)
PGC-1α Overexpression STHdh-q111 cell line ✓ Protects against loss of ΔΨm induced by
3-nitropropionic acid.
(Weydt et al.,
2006)
PGC-1α Overexpression Mouse primary cortical neurons ✓ Protects against cell death induced by oxygen and
glucose derivation.
(Luo et al., 2009)
PGC-1α Overexpression Rabbit renal proximal tubular cells ✓ Promotes recovery from mitochondrial dysfunction
when expressed after oxidative insult.
(Rasbach et al.,
2010)
PGC-1α Upregulation induced by
PPARγ agonists
SH-SY5Y neuroblastoma cell line ✓ Protects against glucose deprivation induced cell death. (Miglio et al.,
2009)
PGC-1α Overexpression Mouse primary cortical neurons
(Tg2576 AD)
✓ Protects against amyloidogenic Aβ accumulation (Qin et al., 2009)
PGC-1α Overexpression In vivo injection in mouse brain ✓ Prevents the loss of DA neurons induced by PARIS
overexpression
(Shin et al., 2011)
PGC-1α Overexpression STHdh-q111 cell line, primary mouse
striatal neurons
✓ Protects against mutant huntingtin induced toxicity. (Cui et al., 2006)
Cancer
PGC-1α Overexpression HepG2 cell line ✓ Reduces troglitazone-induced cell death. (Liao et al., 2010)
PGC-1α Overexpression HeLa cervical cancer cell line ✓ Inhibits C2 ceramide induced death. Partial inhibition of
staurosporine induced cell death.
(Bianchi et al.,
2006)
PGC-1α Overexpression SK-BR-3 breast cancer cell line ✓ Increases expression of uridine phosphorylase. (Kong et al.,
2009)
PGC-1α Upregulation induced by
PPAR-β/ δ agonist
H1838 and H2106 non-small cell
lung carcinoma cell lines
✓ Stimulates cell growth through PI3K/AKT pathway. (Han et al., 2009)
PGC-1α siRNA silencing Prostate cancer cell lines ✓ Inhibits cell proliferation and induces G1 phase cell cycle
arrest.
(Shiota et al.,
2010)
PGC-1β siRNA silencing SK-BR-3 and MCF7 breast cancer cell
lines
✓ Inhibits proliferation. Restores antiproliferative effect of
tamoxifen to tamoxifen-resistant MCF7 cells.
(Deblois et al.,
2010)
PRC shRNA silencing U20S osteosarcoma cell line ✓ Decreases proliferation in glucose and galactose only
medium.
(Vercauteren
et al., 2009)
PRC Overexpression FTC-133, XTC.UC1 and RO 82 W-1
thyroid cell lines
✓ Promotes cell growth. (Mirebeau-
Prunier et al.,
2010)
PGC-1α Upregulation induced by
PPAR-β/ δ agonist
HeLa, 143B, MDA-MD-231 x Decreases growth rates in glucose-containing medium (Wang and
Moraes, 2011)
PGC-1α Overexpression HO8910 epithelial ovarian cancer cell
line
x Induces apoptosis. (Zhang et al.,
2007b)
Cardiovascular system
PGC-1β Knockout Mouse heart ✓ Required for normal chronotopic response (Lelliott et al.,
2006)
PGC-1α Knockout Mouse heart ✓ Required for postnatal growth of the the heart (Leone et al.,
2005)
PGC-1α Knockout Mouse heart ✓ Protects against traverse aortic constriction induced
cardiac stress (apoptosis)
(Arany et al.,
2006)
PGC-1α Knockout Mouse heart ✓ Lack of both coactivators lead to perinatal heart failure (Lai et al., 2008)
PGC-1β
PGC-1α Overexpression Rat cardiomyocytes ✓ Protects from apoptosis in a stress induced cardiac
failure model
(Sano et al., 2004)
PGC-1α siRNA silencing Primary mouse vascular smooth
muscle cells
✓ Augments angiotensin II induced rise in intracellular
ROS and hypertrophy.
(Xiong et al.,
2010)
PGC-1α Overexpression/knockout Mouse ✓ Angiogenesis (Arany et al.,
2008)
PGC-1α Overexpression Human aortic endothelial cells ✓ Inhibits linoleic acid-induced apoptosis. (Won et al., 2010)
PGC-1α Overexpression Human umbilical vein endothelial
cells
✓ Protects against H2O2 or high glucose induced apoptosis. (Valle et al.,
2005)
PGC-1α In vivo transgene
expression
Mouse heart x Cardiomyopathy in adult heart (Russell et al.,
2004)
PGC-1α Overexpression Mouse cardiac-derived H9c2 cell line x Increases cell death after anoxia-reoxygenation injury. (Lynn et al., 2010)
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in yeast cells with compromised mitochondrial function is not under
the control of the Rtg1p/Rtg3p complex. Secondly, genomewide proﬁl-
ing of different yeast strains or of yeast under altered metabolic states,
for example under glucose repression of mitochondrial respiration,showed modiﬁed expression of a largely different set of genes than in
response to mtDNA depletion (Traven et al., 2001). Moreover, overlap-
ping but distinct sets of genes are responsive to inhibition of mitochon-
drial function by means of directly inhibiting respiratory complex III by
antimycin, the ATP synthase by oligomycin, uncoupling of the electron
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to those genes of which expression is altered following mtDNA deple-
tion, further indicating that response pathways speciﬁc to the site of a
metabolic defect exist (Epstein et al., 2001; McCammon et al., 2003).
The upregulation of the multidrug resistance transporter Pdr5p, medi-
ated by the Pdr1p and Pdr3p transcription factors in response to com-
prised Fo function of the ATP synthase represents an example of
retrograde mitochondrion–nucleus signalling not controlled by the
Rtg1p/Rtg3p complex (Zhang and Moye-Rowley, 2001), and further
studies will be essential to identify additional mediators of such signal-
ling. Of note, Rtg2p, the main ‘switch’ of the yeast retrograde response
pathway, also functions as a nuclear coregulator, forming part of the
SLIK (SAGA-like) transactivation complex at the promoters of retro-
grade response target genes (Pray-Grant et al., 2002).
3.2. Diverse pathways of mitochondrial-nuclear retrograde signalling in
mammalian cells
While the existence of a fundamental yeast mitochondria–nucleus
retrograde signalling pathway is well established, at least two further
outstanding questions still remain largely elusive; ‘What are the primary
signals leading to the activation of the pathway?’ and ‘Howwell are these
retrograde signalling pathways conserved in multicellular organisms,
particularly in mammals?’. Studies on the mammalian mitochondrial-
nuclear retrograde signalling pathways have revealed a remarkable het-
erogeneity in both the primary signals resulting frommitochondrial dys-
function and in the downstream nuclear TFs consequently activated
(Fig. 2). To date at least four key primary signals have been recognised
to directly result from mitochondrial dysfunction: (i) reduction of
mitochondrial and cellular ATP levels; (ii) changes in the cellularFig. 2. Key regulators of mitochondrion–nucleus retrograde signalling. Mitochondrial dysf
activity of key signalling pathways which in turn regulate the expression and function
been implicated in this retrograde response, a number of which are here highlighted.NADH/NAD+ ratio; (iii) disequilibrium of free radical production and
cellular oxidative defences; and (iv) deregulation of cellular Ca2+
homeostasis. These signals are less studied in yeast, but they appear to
play a key role in retrograde signalling in mammalian cells. In addition,
glutamate might also function as a primary metabolic signal, given its
role as a potent suppressor of Rtg2p signalling in yeast. In response to
these primary triggers, several nutrient sensing and stress signalling
pathways have been implicated in the mammalian mitochondria-nu-
clear communication, targeting a wide range of transcriptional factors
in the nucleus. Interestingly, no clear homologies to the components
of the yeast system have yet been identiﬁed.
Up-regulation of nuclear encoded mitochondrial (citrate synthase,
Cox-Va, (Marusich et al., 1997)) and non-mitochondrial (ß-actin, myc,
GAPDH (Wang and Morais, 1997)) genes in response to mitochondrial
dysfunction was ﬁrst demonstrated in different mammalian cell types
at the end of the 1990's, followed by a series of studies exploring
the nature of the retrograde signalling pathway, also referred to as
the mitochondrial stress pathway, in C2C12 myoblasts and A549
human lung cancer cells by the group of Avadhani (Amuthan et al.,
2002; Biswas et al., 1999). These studies found elevated basal cytosolic
[Ca2+], together with the overexpression of ER Ca2+ release channels,
and reduced cellular [ATP] in spite increased glycolytic pathways in
mtDNA depleted cells, setting the paradigm of primary mitochondrial
signals triggering the retrograde response in mammalian cells. Of
note, the causal relationship between mitochondrial dysfunction and
deregulated Ca2+ signalling has been shown by independent studies,
in which Ca2+ chelation alone was sufﬁcient to abolish the changes
observed (Arnould et al., 2002; Luo et al., 1997).These studies showed
marked activation of heterogeneous cellular stress responses linking
mitochondrial dysfunction to the activation of a set of nuclearunction may alter cellular Ca2+, redox and energetic homeostasis, and modulate the
of multiple nuclear coregulators and TFs. A wide array of signalling molecules have
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tween the mitochondrial and nuclear genomes. These pathways in-
clude calcineurin mediated activation of NFAT signalling coupled
to increased activity of ATF2, activation of NFκB (Biswas et al., 1999;
Biswas et al., 2008), MAPK (Amuthan et al., 2002; Luo et al., 1997)
and protein kinase C (PKC) (Amuthan et al., 2001), as well as Cam-
KIV mediated CREB activation (Arnould et al., 2002). The involvement
of the transcription factors Egr-1 and CEBP downstream of MAPK and
PKC signalling has also been suggested (Butow and Avadhani, 2004).
More recent studies on the mitochondrial stress response follow-
ing both acute and chronic depletion of mtDNA or pharmacological
inhibition of mitochondrial function further conﬁrmed the remark-
able diversity of such signalling in mammalian cells. While the role
of Ca2+ mediated CREB activation in adaptive mitochondrial biogen-
esis in rho0 cells has been further conﬁrmed (Mercy et al., 2005),
novel mediators have also been identiﬁed. Dissipation of ΔΨm was
shown to speciﬁcally inhibit tyrosine phosphorylation of a deﬁned
set of proteins (Luo and Ingram, 2001), likely reﬂecting calcineurin
mediated upregulation and activation of the insulin like growth fac-
tor-1 receptor, triggering increased glucose uptake and utilisation
by aerobic glycolysis (Guha et al., 2007). Similarly, a pathway acting
through PI3K and Akt activation was shown to enhance the formation
of a transcriptional activator complex, mediated by the phosphoryla-
tion of heterogeneous nuclear ribonucleoprotein (hnRNP) A2 as a
coactivator. This complex, formed by NFκB c-Rel/p50, C/EBPβ, CREB,
and NFAT, is responsible for upregulation of Glut4, Cathepsin L and
the RyR1 gene expression, prototypical genes upregulated by mito-
chondrial stress in C2C12 cells and other cancer cell lines (Guha
et al., 2010; Guha et al., 2009). Alongside activation of novel signalling
pathways, a series of studies have also considered other primary sig-
nals resulting as direct consequence of mitochondrial dysfunction in
mitochondrion–nucleus retrograde signalling. An imbalance between
the supply of reducing equivalents and ﬂow through the electron
transport chain due to compromised function of respiratory com-
plexes is one of the main sources of cellular reactive oxygen species
(Murphy, 2009), and indeed increased ROS generation has been
shown to convey signals to a wide array of cellular targets (for re-
views see e.g. (Droge, 2002; Jones, 2008)). Mitochondrial ROS have
thus also been implicated in crosstalk between the mitochondria
and nucleus, regulating cytochrome c1 and b expression (Suzuki
et al., 1998), a response which probably involves NFκB, NRF-1 and
TFAM (Miranda et al., 1999; Piantadosi and Suliman, 2006). Still, there
is no clear understanding of the components involved in this ostensibly
pleiotropic pathway, reﬂected by studies involving H2O2 as a primary
trigger in AMP kinase-mediated (Irrcher et al., 2009) or CREB-mediated
(St-Pierre et al., 2006) mediated mitochondrial biogenesis, or even ret-
rograde regulation of the Drosophila cell cycle, in which AMP and ROS
appear to act independently through ASK-1, FOXO and p27 (Dacapo)
(Owusu-Ansah et al., 2008), aswell as stem cell proliferation and differ-
entiation (Mandal et al., 2011). In addition to ROS, the involvement of
nitric oxide and carbon monoxide signalling pathways has also been
suggested to play a part in mammalian retrograde signalling (Butow
and Avadhani, 2004; Le Pennec et al., 2011; Rhodes et al., 2009).
These factors undoubtedly can function as triggers of mitochondrial
biogenesis (see e.g. (Nisoli et al., 2003)), but their role as bone ﬁde
retrograde signals awaits veriﬁcation.
Finally, even though they have not yet been demonstrated to play a
direct role in mitochondrion–nucleus communication, we should men-
tion two recently characterised pathways linking changes in cytosolic
NADH/NAD+ratios to alterations in nuclear transcriptional activity.
First, an attractive hypothesis would associate reduced cellular energy
levels, characterised by diminished NADH/NAD+ ratios, to NAD+medi-
ated activation of the sirtuin family of deacetylases. According to this
pathway, activation of Sirt1 in turn would lead to the activation of
PGC-1α, mediating mitochondrial biogenesis to re-establish cellular
energy levels (Nemoto et al., 2005). However, since the free cytoplasmicand presumably nuclear NADH/NAD+ ratio was estimated to approxi-
mately 1:700 (Williamson et al., 1967), even substantial reduction in
NADH levels would not lead to signiﬁcant changes in the absolute
[NAD+]. Alternatively, it has been recently proposed that increased
AMP/ATP ratios, due tomitochondrial dysfunctionwould lead to activa-
tion of AMPK, which has been shown to signal energy depletion to Sirt1
by increasing absolute NAD+ levels (reviewed in (Jeninga et al., 2010)).
On the other hand, cytosolic NADH was proven to speciﬁcally bind to
carboxyl-terminal binding protein (CtBP), a transcriptional corepressor
(Fjeld et al., 2003), leading to its translocation to the nucleus (Verger et
al., 2006). Since inhibition of the mitochondrial electron transfer chain
leads to elevated NADH levels, and CtBP was shown to modify the ac-
tivity of a series of TFs and coregulators, including PGC-1α and
Sirt1 (Kajimura et al., 2008; Zhang et al., 2007a), this pathway
might represent a genuine mitochondrion–nucleus feedback loop.
3.3. Evolutionarily conserved, common features of mitochondrion–nucleus
signalling
The studies of retrograde signalling in mammalian model systems
summarised above have demonstrated the fundamental role of mito-
chondrial function in controlling cellular homeostasis through interac-
tion with the nuclear genome. Moreover, they also reﬂect the
evolutionary divergence from the yeast retrograde signalling pathway,
which primarily concerns metabolic adaptation, to a much broader
framework of stress signalling, ultimately governing cell fate. Although
not within the strict scope of the review, we must mention two related
trends in the ﬁeld substantiating this view. Firstly, the intimate link
with NFκB controlled stress signalling has led to the proposal of evolu-
tion of yeast retrograde signalling into the cellular defence pathways of
innate immunity, oxidative defence and the unfolded protein response,
while the homology of the bHLH/zip domain of Rtg1/3 proteinswith the
Myc/Max/Mad related protein network suggests further links to cellular
proliferation, metabolism and cell death (Srinivasan et al., 2010).
Secondly, mitochondrial dysfunction elicited in a manner similar to
the unfolded protein response (UPR) of the endoplasmic reticulum
has recently gained attention. Accumulation of misfolded proteins in
the mitochondrial matrix, partly as a consequence of compromised ex-
pression of the mitochondrially encoded proteins, has been shown to
induce an organelle speciﬁc mitochondrial UPR (UPRmt) (Martinus
et al., 1996), and a series of studies have unveiled a novel, evolutionarily
conserved adaptive signalling pathway between mitochondria and the
nucleus (recently reviewed in (Baker and Haynes, 2011; Baker et al.,
2011; Broadley and Hartl, 2008). The transcription factors implicated
in UPRmt, such as CHOP and CEBP, partially overlap with the proposed
mammalian retrograde response targets, but the upstream signals ap-
pear to be distinct (e.g. JNK2 (Horibe and Hoogenraad, 2007)). Again,
the latter pathway well illustrates the diversity of cellular responses
and signalling pathways linked to mitochondrial dysfunction, and for
further information on its role in pathologies we refer the reader to
(Moisoi et al., 2009; Siegelin et al., 2011)) and the above cited recent
reviews.
3.4. Potential pathological implications of mitochondrion–nucleus
retrograde signalling involving the PGC-1 family coactivators
The pleiotropic nature of cellular responses induced by mitochon-
drial stress means that their contribution to pathological states is an
overt postulation. For instance, in the case of cancer, several studies
have suggested that artiﬁcial depletion of mtDNA results in the devel-
opment of an invasive cancer phenotype. The effect is suggested to be
mediated by mitochondrion–nucleus retrograde signalling and in-
cludes several mechanisms, e.g. the upregulation of metastatic
markers TGFβ1 and cathepsin-L (Amuthan et al., 2002; Amuthan
et al., 2001; Guha et al., 2009); conferring resistance to apoptosis by
altering the anti- and proapoptotic Bcl-2 family rheostat (Amuthan
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(Biswas et al., 2008; Guha et al., 2007); and perturbing the p53 net-
work and causing genomic instability (Kulawiec et al., 2008). Similar-
ly, as reviewed recently, mitochondrial dysfunction can contribute to
several other major pathologies such as neurodegeneration and car-
diovascular disease through multiple, varied mechanisms (Duchen
and Szabadkai, 2010). In this section we discuss the small number
of available studies where retrograde signalling, triggered by primary
mitochondrial dysfunction, targets speciﬁcally the PGC-1 family of
coactivators. In general, in these studies the retrograde signals in-
volved are poorly characterised, and the examples presented involve
a number of pathways and regulators upstream of PGC-1 family ex-
pression and activation, as detailed in the ﬁrst section and recently
reviewed in (Hock and Kralli, 2009; Lin et al., 2005a; Scarpulla,
2011). The outcome of such a signalling, given the broadly cytopro-
tective role of the PGC-1 family in cellular physiology, follows two
general patterns depending upon the particular pathology. In diseases
characterised by increased susceptibility to cell death such as neuro-
degenerative, neuromuscular and cardiovascular diseases, retrograde
activation of PGC-1 is expected to play a protective role. In contrast, in
cancer, PGC-1 mediated promotion of cell proliferation and survival
would contribute to disease progression.
Human mtDNA encodes 37 genes, including 22 mitochondrial
tRNAs, 2 mitochondrial rRNAs and 13 proteins, which are essential
components for OXPHOS. In addition mtDNA also contains a displace-
ment loop (D-loop) region, which is essential for both the transcription
and replication of the mtDNA (Fish et al., 2004; Kelly and Scarpulla,
2004). In comparison to nuclear DNA, mtDNA undergoes a faster rate
of mutation due to a variety of factors, notably that mtDNA lacks in-
trons, protective histones and has limited DNA repair capacity. Further-
more,mtDNA is located close to themitochondrial innermembrane and
is therefore vulnerable to oxidative damage due to continuous exposure
to ROS generated during OXPHOS (Chandra and Singh, 2011a). Since
the identiﬁcation of the ﬁrst pathogenic mtDNA mutations in 1988
(Holt et al., 1988)more than 250 pathogenicmtDNA alterations, includ-
ing point mutations and rearrangements, have been found to cause a
range of diseases (Tuppen et al., 2010; Wallace, 2010). Germline
mtDNA rearrangements and point mutations may lead to a broad spec-
trumof diseases, such asmitochondrialmyopathies or encephalopathies,
Leber's hereditary optic neuropathy (LHON), chronic progressive exter-
nal ophthalmoplegia (CPEO), Leigh syndrome, Kearns–Sayre syndrome,
Myoclonic Epilepsy with Ragged Red Fibers (MERRF), ‘Mitochondrial
Myopathy, Encephalomyopathy, Lactic Acidosis, Stroke-like Symptoms’
(MELAS) maternally-inherited diabetes and deafness, neuropathy,
ataxia, and retinitis pigmentosa (NARP) syndrome (Swerdlow, 2009;
Taylor and Turnbull, 2005; Wallace, 2010). Accumulation of somatic
mtDNA mutations is also associated with ageing and age-related dis-
eases such as cancer and neurodegenerative diseases (Reeve et al.,
2008; Swerdlow, 2009). Importantly, increased mtDNA mutation load
has been reported in sporadic diseases including Alzheimer's disease
and Parkinson's disease (Lin et al., 2002b; Simon et al., 2004; Smigrodzki
et al., 2004). As pathogenic mtDNAmutations will affect either the main-
tenance of the mtDNA or alter the function and assembly of core compo-
nents of the respiratory chain complexes, the ultimate outcome of those
mutations is likely to be defects in OXPHOS. A limited number of studies
have suggested a possible link between OXPHOS defects and a retro-
grade signalling pathway to nuclear factors regulating transcription
such as PGC-1α to promote mitochondrial biogenesis, although the
mechanisms of such signalling require further investigation. In in vitro
cellular models, exposure to high concentrations of respiratory uncou-
plers was shown to cause Ca2+ mediated up-regulation of PGC-1α
(Rohas et al., 2007), whereas ROS was suggested to have the same ef-
fect in adaptive responses to even subtle changes in OXPHOS activity
caused by common mtDNA sequence variants in different mouse
strains (Moreno-Loshuertos et al., 2006) as well as in neurodegenera-
tive disease (St-Pierre et al., 2006). Increasedmitochondrial content inthe skeletal muscle of patients with impaired OXPHOS due to mtDNA
mutations has been reported since the late 1980s (Lombes et al.,
1989;Moraes et al., 1989; Shoubridge et al., 1990), whichmight reﬂect
PGC-1α upregulation, as shown in skeletal muscle of mitochondrial
myopathy patients with various mtDNA mutations (Adhihetty et al.,
2007). However, other studies suggest that retrograde signalling
from mitochondria to the nucleus is not always activated in all cells
harbouring pathogenic mtDNA mutations. For example, PGC-1α ex-
pression was unaltered in ﬁbroblasts from patients with G13513A,
T9185C or A3260C mutations (Menzies et al., 2009) and CREB activation
was not observed in skeletal muscle from patients harbouring the
A3243G mtDNA mutation or the common 4977 bp mtDNA deletion
(Crimi et al., 2005). Similarly, no change in PGC-1α expression was
observed in MELAS (Joseph et al., 2004) or NARP (Wojewoda et al.,
2011). The lack of a mitochondrion–nucleus compensatory loop in
some cases was attributed to its replacement by an intramitochondrial
feedback mechanism, comprising the activation of a soluble mitochon-
drial adenylate cyclase and consequent PKA mediated phosphorylation
and activation of complex IV (Acin-Perez et al., 2009). Altogether, these
and other studies suggest that the feedback control of nuclear TFs by pri-
mary mitochondrial defects may follow a tissue and condition speciﬁc
pattern, potentially involving PGC-1 family mediated cellular survival.
However, no studies have yet directly demonstrated such an inherent
protective mechanism in neurodegenerative and cardiovascular disease,
warranting further investigation, particularly in view of the beneﬁcial
role of direct, experimental activation of mitochondrial biogenesis in
these diseases.
Somewhat more information has been obtained on the role of
mtDNA integrity, mitochondrial function and retrograde signalling
to the PGC-1 family of coactivators in cancer. Extensive sequencing
of the mitochondrial genome has revealed that approximately 40–
70% of all tumours carry mtDNA alterations, including deletions, in-
sertions and missense mutations (Kaipparettu et al., 2010). In addi-
tion to pathogenic mtDNA mutations, certain polymorphisms in
mtDNA have also been associated with a predisposition to age-related
diseases. For instance, mitochondrial haplogroup U is associated with
increased risk of developing prostate cancer and renal cancer (Booker
et al., 2006). The A10398G and T16519C polymorphisms increase the
risk of developing breast cancer in European–American females,
whereas conversely the T3197C and G13708A polymorphisms were
found to decrease the risk (Bai et al., 2007). A complete description
of all known pathogenic mtDNA mutations and associated diseases
is beyond the scope of this review, however a current and updated
list of all known mtDNA mutations and polymorphisms can be
found in the MitoMAP database (http://www.mitomap.org), and the
topic of cancer related mtDNA mutations has been extensively
reviewed recently (Brandon et al., 2006; Chandra and Singh, 2011b;
Czarnecka et al., 2010; Kulawiec et al., 2010). As discussed above,
there is compelling evidence that mitochondrial stress can be causal
to the development of various hallmarks of cancer, representing a po-
tential link to primary somatic mtDNA mutations in cancer cells. A
speciﬁc mutation, unleashing retrograde ROS signalling involving
Mcl-1 and HIF1α has been shown to contribute to the development
of a metastatic phenotype (Ishikawa et al., 2008a; Ishikawa et al.,
2008b), while Akt hyperphosphorylation in the absence of elevated
ROS was also able to elicit a similar effect (Kulawiec et al., 2009). Im-
portantly, among the heterogeneous retrograde pathways a few stud-
ies have also addressed the role of the PGC-1 family as targets in
cancer cells with mtDNA defects. Wenz and colleagues found that
the expression of PGC-1α was increased by 3-fold in galactose-resis-
tant clones of a cybrid cell line carrying a homoplasmic mutation
(G5703A) in a mtDNA encoded tRNA (Wenz et al., 2010). The same
group has also reported upregulation of both PGC-1α and PGC-1β
as a consequence of mutations in the ND5 and COXI genes (Srivastava
et al., 2007). Furthermore, CREB, a nuclear TF that is known to act at
the PGC-1α promoter, was found to be activated in mtDNA-depleted
95A.W.E. Jones et al. / Mitochondrion 12 (2012) 86–99murine ﬁbrosarcoma cells and human osteosarcoma cells, as well as
in cybrid cells harbouring the A8344G mtDNA mutation (Arnould et
al., 2002; Mercy et al., 2005). Clinically even more relevant results
on this subject were obtained on a subset of tumours with aberrant
mitochondrial proliferation, termed oncocytomas. In these neo-
plasms, mitochondrial defects, mostly due to mtDNA mutations
encoding various complex I subunits, trigger compensatory upregula-
tion of mitochondrial biogenesis as recently reviewed (Gasparre et al.,
2011). Although the nature of the primary signal is debated, the in-
volvement of PGC-1 family coactivators was demonstrated in this ret-
rograde response. In a subset of thyroid oncocytic tumours PRC was
shown to be the primary target of NO and Ca2+ mediated signals
(Le Pennec et al., 2011; Savagner et al., 2003), whereas in in vitro cel-
lular models of oncocytomas, varying the PRC:PGC-1α ratio appears
to set the balance between the oxidative and glycolytic phenotypes
(Mirebeau-Prunier et al., 2010). Additionally, the occurrence of onco-
cytic-like foci in the development of endometrial carcinomas was
found to be associated with induction of several PGC-1 family target
genes (Guerra et al., 2011). Overexpression of PGC-1 family member
thus appears to positively correlate with pathogenic changes in cellu-
lar function in certain types of cancer cells.
4. Conclusions
Mitochondrial biogenesis is a fundamental cellular process, re-
quired both to maintain a functional population of mitochondria ca-
pable of meeting cellular energy demands in the face of continual
molecular turnover in the mitochondrial network, and as an adaptive
mechanism in response to varying energetic requirements. Thus, the
ability to synthesise and assemble mitochondrial components is
vital for cell survival.
Uniquely amongst the organelles of animal cells, mitochondrial
biogenesis falls under the control of two genomic systems, the nuclearFig. 3. Retrograde mitochondrion-nuclear regulation of cell fate. Mitochondrial
dysfunction may cause ﬂuctuations in cellular Ca2+, energetic and redox homeostasis
and in turn modify the expression and/or activity of nuclear TFs. Subsequent alterations
in the expression of nuclear target genes regulated by these TFs constitutes a retrograde
mitochondrion–nucleus signalling response. This response may promote cellular adapta-
tion, survival, growth or proliferation. Conversely, it can also contribute to senescence
or ultimately activate cell death pathways, depending on the genetic or environmental
background of the cell. Where deregulation of these processes underpins disease, such
retrograde signalling may contribute to pathology.genome and mtDNA respectively. The need to co-ordinate the produc-
tion and assembly of protein components from separate genetic sys-
tems, accompanied by the import of further constituents such as lipids
from remote sites of synthesis, has lent itself to the development of
complex regulatory networks of transcription. Such transcriptional net-
works rely upon the concerted action and interaction of multiple NRs
and TFs for appropriate gene expression. Coregulators acting as part of
multiprotein complexes both to promote and to suppress the activity
of NRs and TFs directly and through modiﬁcation of regulatory ele-
ments add a further level of ﬁne control, which may exert inﬂuence
in a cell-type speciﬁc manner. Finally, numerous signalling pathways
and patterns of gene expression converge upon these biogenesis
factors to integrate the energetic needs of the cell, tissue and entire
organism into an apposite programme of transcription.
The PGC-1 family of coactivators function as master regulators of
cellular metabolism and mitochondrial biogenesis, and sit at a hub
of cellular signalling. Activation or repression of the transactivating
function of the PGC-1 family members may drastically alter cellular
metabolic activity both directly and indirectly related to mitochon-
dria. Indeed, dysfunction of PGC-1 family coactivators may underlie
pathology associated with a diverse range of diseases, including car-
diovascular disease, neurodegeneration and cancer. Whilst the nor-
mal and pathological regulation of the PGC-1 family remains under
investigation, modiﬁcations at both the level of transcription and
post-translation appear to play a role.
Dysfunction of mitochondria (also termed mitochondrial stress) is
now a well-established characteristic of many disease states. These
defects are either due to primary mitochondrial alterations, resulting
from mutations in mtDNA or nuclear genes encoding mitochondrial
proteins, or are the consequence of pathological processes in other
cellular compartments. The direct consequences of mitochondrial
stress, such as cellular energetic and redox crisis, have a widely recog-
nised pathophysiological role, but the ability of mitochondria to gener-
ate signals capable of affecting global patterns of nuclear transcription
has not been so widely discussed. Whilst such mitochondria–nucleus
retrograde signalling pathways have been described in yeast for some
time, the functions andmolecular details of comparable communication
in mammalian cells have only just begun to emerge. Such mammalian
retrograde signalling may be mediated by heterogeneous signals, in-
cluding altered Ca2+ homeostasis, an imbalance in cellular redox state
and unsteady ATP levels. Primary mitochondrial dysfunction may also
modulate these key parameters, modifying the activity of multiple
cellular signallingpathways toﬁnally target a large set of transcriptional
coregulators and transcription factors, and consequentially fundamen-
tally alter the transcription of nuclear genes (Fig. 3). We have here dis-
cussed the available studies which describe such links between
mitochondria and the nucleus, speciﬁcally those targeting the PGC-1
family of coactivators. Such retrograde signalling could promote ﬁne
and rapid adaptation to changing bioenergetic requirements, however
pathophysiological signalling by these means, such as during chronic
impairment of OXPHOS produced by mtDNA mutations, may alter the
global pattern of gene expression in either a beneﬁcial or maladaptive
fashion, depending on the particular pathology. Importantly, a primary
mitochondrial defect could conceptually therefore impinge upon cell
fate by altering gene expression patterns which are not obviously con-
nected to the initial mutation, and might explain how varied mtDNA
mutations converge upon similar phenotypes. Further investigation of
the mitochondrion–nuclear signalling thus could yield new treatment
strategies and pharmacological targets for a wide range of disorders.
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